Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Burjeel Holdings and US-based Northwell Health To Launch Neuroscience Institute in UAE

As part of its ongoing efforts to bring complex care and to increase the flow of international patients to the UAE, Burjeel Holdings (“Burjeel” or “the Group”), one of the largest healthcare services providers in the MENA, has joined hands with Northwell Health, the largest healthcare provider in New York State, to launch a highly advanced Neuroscience Institute in Abu Dhabi.

The Neuroscience Institute will be located at Burjeel Medical City (BMC), the flagship facility of Burjeel Holdings, and will provide state-of-the-art care for adult and pediatric patients with neurological disorders, including autoimmune brain disorders, epilepsy, Parkinson’s and movement disorders, pediatric neurology, and multiple sclerosis. The collaboration between Burjeel Holdings and Northwell Health will enable the transfer of knowledge and expertise between the two organizations to deliver the best possible patient care.

World-renowned neurologist Dr. Souhel Najjar, professor and chairperson of the Department of Neurology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and executive director and senior vice president of the Northwell Health Neurology Service Line, will head the Institute in Abu Dhabi.

Dr. Souhel Najjar commented: “Northwell Health and Burjeel Holdings’ decision to build a neuroscience institute in the UAE demonstrates their synergistic culture of innovation and commitment to bring advanced, innovative, and compassionate neurological care to the UAE and the entire Middle East. On a personal level, I am proud of this relationship as it allows me to bring my Northwell Health family closer to the beloved UAE.”

Burjeel Holdings and Northwell Health formalized the establishment of the Dr. Najjar Neuroscience Institute at a ceremony held in New York at the Northwell Health corporate headquarters in Manhattan. The ceremony was attended by Dr. Shamsheer Vayalil, founder and chairman of Burjeel Holdings; Mr. John Sunil, CEO, Burjeel Holdings; Dr. Mohan Chellappa, non-executive director, Burjeel Holdings; Michael Dowling, president and CEO, Northwell Health; Dr. Souhel Najjar, SVP and executive director of the Neurology Service Line, Northwell Health; Dinelia Ortiz, vice president, Neurology Service Line, Northwell Health; Serena Najjar, senior project manager, Neurology Global Patient Services, Northwell Health; Kevin Beiner, SVP and regional executive director western region, Northwell Health.

Michael J. Dowling said: “This collaboration is an exciting opportunity to deliver world-class care to the communities of Abu Dhabi. Dr. Najjar has long been an example of clinical excellence for our health system and we are incredibly proud to see his team’s services offered across the globe.”

John Sunil, CEO, Burjeel Holdings added: “The partnership is another important step in the Burjeel Holdings’ commitment to delivering unmatched healthcare excellence in the region and greatly improving patient outcomes. The collaboration with Northwell Health and Dr. Najjar aligns with the Group’s endeavors to provide complex care and access to the newest treatments and technologies for patients across the region.”

Northwell Health’s Neurology Service Line is a regional and international destination for neurological care, committed to improving patient outcomes and driving innovation. Patients from all over the world can receive premier treatments for a wide spectrum of neurological disorders from renowned experts in the field.

Burjeel Medical City is a 400-bed leading quaternary care facility with cutting-edge medical technology and employing internationally recognized and published physicians. The Neuroscience Institute at the hospital will be supported by state-of-the-art medical technology and an international team of experts certified by top global medical boards.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy